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In this issue of the Biomedical Journal, we take a look at some of the immune system's most
peculiar cells, invariant natural killer T cells, which have features of both innate and
adaptive cells. We also highlight a clinical study revealing that high serum phosphate
levels could show that it's time to start dialysis in patients with chronic kidney diseases.
Finally, this issue also includes some case reports, including an unusual case of aspergil-
losis related to long-term inhaler use.iNKT cell
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Fig. 1 e Despite the fact that they express a T cell receptor,
invariant Natural Killer T (iNKT) cells have several properties
typical of cells of the innate immune system.Spotlight on reviews
The two faces of invariant natural killer T cells
The theoretical fence between what constitutes innate im-
munity and what constitutes adaptive immunity was erected
many decades ago. Yet once in a while, there comes a chal-
lenger that defies classification. This issue of the Biomedical
Journal includes two reviews describing invariant natural killer
T cells (iNKTs), T cell receptor-expressing cells with an
emerging role in many human diseases that have been
baffling researchers with their innate-like features.
In their review, Birkholz and Kronenberg [1] describe some
of the properties and antigens of these curious cells. A hybrid
by nature, iNKT cells express both markers of innate natural
killer (NK) cells, such as CD161, and a ab T cell receptor (TCR)
with some unusual properties [Fig. 1]. Unlike conventional T
cells that recognize peptides bound to highly polymorphic
major histocompatibility complex (MHC) class I and II mole-
cules, the TCR of iNKT cells recognizes lipid antigens bound tom.
g Gung University.
iversity. Publishing servi
mons.org/licenses/by-nca the poorly-polymorphic CD1d molecule. All in all, this
combination of traits gives rise to a cell capable of rapidly
secreting copious amounts of cytokines and cytotoxic gran-
ules in response to the activation of its TCR by a specific self or
foreign lipid ligand [2].ces provided by Elsevier B.V. This is an open access article under
-nd/4.0/).
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lergens and play a role in many diseases [3e5]. Tard et al. [6]
describe how our understanding of the role of these cells in
diabetes has progressed ever since the early finding of reduced
iNKT cells numbers in diabetic (type I) NOD mice [7]. Func-
tional experiments soon followed, with the demonstration
that the transfer of iNKT cells to NOD mice protected them
from developing diabetes [8], while a similar protective effect
was brought about by the injection of the iNKT cell-
stimulating lipid, a-galactosylceramide (a-GalCer) [9]. This
protection is thought to be mediated in part through IL-4,
which is abundantly secreted by iNKT cells following their
stimulation and prevents the onset of diabetes [10]. In addi-
tion, iNKT cells inhibit the differentiation of autoreactive T
cells responsible for the destruction of pancreatic b-cells [11].
Despite these clear findings in mice, human studies of
iNKT cells in type I diabetes have yielded inconsistent results,
with studies reporting similar, high or low frequencies of iNKT
cells in diabetic patients. This may be because iNKT numbers
vary greatly from person to person (ranging from 0.01% up to
nearly 1% of peripheral lymphocytes) [2]. Nonetheless, this
has not precluded the testing of iNKT-stimulating therapies,
with studies underway to develop optimized a-GalCer analogs
[12]. Such therapies could also be relevant for patients with
type II diabetes, in light of growing evidence that these
glycolipid-recognizing cells play a role in obesity-related
inflammation and insulin resistance [13].
iNKT cells may well have earned a reputation as the duck-
billed platypus of the immune system, but despite their
confusing appearance, one thing remains clear: their wide-
spread role in human diseases, from diabetes, allergies to
cancer is being uncovered, and we can expect therapies
manipulating this intriguing cell subset in years to come.Spotlight on original articles
Deciding on dialysis: serum phosphate as a biomarker in
chronic kidney disease
Our expanding waistlines coupled with increasing life ex-
pectancy has meant that the prevalence of the chronic kidney
disease (CKD) is one the rise [14]. In the absence of an appro-
priate kidney donor, the only treatment for people with
advanced CKD is dialysis. Yet, determining when exactly to
initiate dialysis is often a complicated decision that varies
from one treatment center to the next. In this issue of the
Biomedical Journal, Lu and colleagues [15] identify high serum
phosphate levels as clinical marker for the initiation of
dialysis.
CKD is a condition characterized by gradual loss of kidney
function over time and affects a staggering 8e16% of people
worldwide [16]. If left untreated, patients may develop life-
threatening complications including pulmonary edema, car-
diovascular disease and extreme hyperkalemia. Renal
replacement therapy, and notably hemodialysis, is a last resort
in the advanced stages of disease, but is costly, and renders
patients dependent on highly frequent hospital visits lasting
several hours. Previous guidelines relied heavily on glomerular
filtration rate (GFR; the rate of blood filtered by the kidneys) as amarker indicating the need for dialysis [17], but several studies
have since shown that starting patients on dialysis at the cut-
off GFR may in fact be harmful in many cases [18,19]. Recent
guidelines offer more room for physician's to use their own
clinical judgement [20]; however, objective laboratory variables
are needed to facilitate this decision.
Lu et al. retrospectively analyzed the medical records of all
patients with advanced stage CKD attending a Taiwanese
tertiary medical center over a four year period and collected
data on demographics, comorbidities, underlying diseases,
duration of nephrology care, use of phosphate binders, and
laboratory findings. They divided patients into two groups: a
dialysis-initiated (n ¼ 209) and non-dialysis (n ¼ 83) group and
evaluated potential risk factors associated with the initiation
of dialysis using logistic regression models. Besides conven-
tional laboratory markers (urea and serum creatinine levels),
serum phosphate levels were significantly associated with the
initiation of dialysis after adjusting for other factors, with a
110% increased risk of initiation for each 1 mg/dL increase of
serum phosphate. Moreover, serum phosphate was the only
tested variable that was within the normal range in the con-
trol group, but very high in the dialysis-initiated group.
It has long been known that high serum phosphate is a
common problem in patients with CKD and may lead to min-
eral bone diseases, vascular calcification and cardiovascular
disease [21], yet its prognostic value is underappreciated. If
replicated in a larger prospective cohort, phosphate levels may
prove to be a powerful biomarker, especially in patients with
complex uremic syndrome, and may help physicians to make
the difficult decision of whether or not to initiate dialysis.Also in this issue:
Review articles
Studying the link between drugs and food in flies
In this review, Landayan and Wolf [22] discuss the use of
Drosophila as a model organism to study overlap in the neural
circuitry controlling the reward sensation associated with
food and drugs.
The challenges of amblyopia treatment
Amblyopia or ‘lazy eye’ occurs if visual signals are not pro-
cessed correctly in the brain, leading to impaired vision that
cannot be corrected by glasses or contact lenses. It has proven
to be a difficult condition to manage, as described by Maco-
nachie and Gottlob in this review [23], where they discuss
some of the challenges and future directions in treatment.
Original articles
Top marks for thyroid nodule malignancy scoring system
Most lumps (or nodules) that appear in the thyroid are
harmless. Risk of malignancy is assessed by fine-needle
aspiration cytology (FNAC), yet until a few years ago, there
existed no standard way to interpret the results of this test. In
this retrospective analysis of 392 FNACs, Arul et al. [24] vali-
date the recently developed Bethesda system for reporting
thyroid cytopathology [25] as an accurate scoring system for
b i om e d i c a l j o u r n a l 3 8 ( 2 0 1 5 ) 4 6 5e4 6 8 467predicting malignancy and identifying patients requiring
further treatment.
High osteonection levels signal danger for chronic heart failure
patients
The collagen-binding protein osteonectin (OSN) controls
extracellular matrix remodeling after myocardial infarction
(MI) [26], but its role in chronic heart failure (CHF) is unclear.
Berezin and Kremer [27] investigate the prognostic value of
OSN in 154 patients with ischemic symptomatic CHF and
surprisingly report that high circulating levels of OSN are
associated with an increased risk of CHF-related death or
readmission.
Bigger is not always better in hip transplants
Advancements in the materials used in hip transplants have
enabled the size of prothestic femoral head to be increased
without increasing wear. However, it is still unclear whether a
large head (>36 mm) may decrease the dislocation rate and
improve hip range of motion. In this retrospective study of 95
patients undergoing ceramic-on-ceramic total hip arthro-
plasty, Lu and colleagues [28] find that functional outcome
and early complications are similar between large and small
femoral heads.
Determining the best methods to train the next generation of
doctors
Postgraduate programs that offer general medical training
were first rolled out in Taiwan in 2003, and are thought to
improve patient care, clinical skills and doctor-patient
communication. Hsu and colleagues [29] use an objective
structured clinical examination to assess learning through
different training programs and find that a 6 month training
program prepares young doctors for clinical practice just as
well as a 1 year training program.
Brief communication
Rare case of aspergillosis evading a healthy immune system
In this case report, Saha et al. [30] describe a curious case of
laryngeal aspergillosis occurring in an immunocompetent
asthmatic individual, likely linked to long-term inhalational
steroid use.
Correspondence
A peculiar case of muscular dystrophy
Ahmad and Kumar [31] report a case of adult onset myotonic
muscular dystrophy type I in a soldier with several unusual
features, including the lack of affected family members or
systemic features and marked atrophy of the tongue.r e f e r e n c e s
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